Details of the Drug

General Information of Drug (ID: DMYXT2U)

Drug Name

Secukinumab

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Approved	[1]
Alopecia	ED70	Phase 2	[2]
Atopic dermatitis	EA80	Phase 2	[2]
Dry eye disease	9E1Z	Phase 2	[2]
Multiple sclerosis	8A40	Phase 2	[2]
Psoriatic arthritis	FA21	Phase 2	[2]
Rheumatoid arthritis	FA20	Phase 2	[2]
Type-1 diabetes	5A10	Phase 2	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Affected Organisms

Humans and other mammals

ATC Code

L04AC10: Secukinumab

L04AC: Interleukin inhibitors

L04A: IMMUNOSUPPRESSANTS

L04: IMMUNOSUPPRESSANTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Monoclonal antibody

Sequence

>Secukinumab Heavy Chain (CAS 875356-43-7)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYY
VGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRG
TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK e format="FASTA">&gt
Secukinumab Light Chain (CAS 875356-44-8)EIVLTQSPGTLSLSPGERA
TLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL
EPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH
QGLSSPVTKSFNRGEC

Cross-matching ID

UNII: DLG4EML025
DrugBank ID: DB09029
TTD ID: D0Q0OD

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2	ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate